a Phase 1 Evaluation of Duvelisib (IPI-145), a PI3K-δ,γ Inhibitor, in Patients with Relapsed/Refractory iNHL

Introduction: Signaling via PI3K-δ and PI3K-γ is essential for both normal and malignant B-cell and T-cell proliferation, survival, and migration. PI3K-δ and PI3K-γ have distinct and complimentary effects on malignant B-cells and nonmalignant immune cells important in tumor immunity and the tumor microenvironment. Duvelisib (IPI-145) is a novel targeted oral PI3K-δ,γ inhibitor in development for the treatment of hematologic malignancies. An ongoing Phase 1 study has demonstrated substantial clinical activity in patients (pts) with advanced hematologic malignancies, including pts with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL).